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Background and aim: The aim of this study is to evaluate whether the long-term (≥4 weeks) use of proton pump inhibitors (PPIs) is a
risk factor for intubation requirement and mortality in patients hospitalized for COVID-19.
Materials and methods: In this multicentric retrospective study, a total of 382 adult patients (≥18 years of age) with confirmed
COVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periods
during which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included those
who have used PPIs for more than 4 weeks.
Results: The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did not
use any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026–1.068),
current smoking (HR: 2.590, 95% CI: 1.334–5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06–2.41) were found
to be independent risk factors for mortality.
Conclusion: The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes for
patients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19
treatment.
Key words: Covid-19, proton pump inhibitors, mortality

1. Introduction
In December 2019, a pneumonia-causing disease was
discovered in Wuhan, China, which was later identified
as COVID-19 by the World Health Organization (WHO)
[1]. COVID-19 spread rapidly throughout the world and
was identified as a pandemic by the WHO in March 2020
[2]. The etiological agent of this disease was named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
because of its phylogenetic similarity with SARS virus.
This disease exhibits a wide spectrum of manifestations,

ranging from asymptomatic disease to pneumonia, severe
respiratory failure, and even death, and it is generally
more severe in the elderly and individuals with comorbid
diseases [3]. COVID-19 primarily affects the respiratory
system and causes severe pneumonia, with the possibility
of ground-glass opacities in the lung and cardiac damage
occurring [4].
Proton pump inhibitors (PPIs) fully inhibit the H+K+-ATPase pump in parietal cells for a long time and
also inhibit basal and stimulated gastric acid secretion for
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up to 16–18 h [5]. Generally, PPIs are superior to other
antisecretory drugs in the presence of gastroesophageal
reflux disease, peptic ulcer, and dyspepsia [6]. Since the
risk of developing tolerance against the effects of PPIs is
low and they remain effective for a long time, they have
been increasingly used in the treatment of acid-related
diseases and have become the first treatment option [7]. It
should, however, be noted that the long-term use of PPIs
may cause some problems, such as vitamin and mineral
absorption disorders, decreased effectiveness of antiplatelet
drugs, increased risk of osteoporotic fractures, and acute
and chronic renal failure [8,9]. It has also been found that
using PPIs causes changes in the intestinal microbiota and
may, therefore, increase the rate of infections due to enteric
pathogens, such as infection with Clostridium difficile [10].
Moreover, it has been shown that the reduced gastric
acidity (hypochlorhydria) resulting from long-term PPI
use may cause an increased risk of community-acquired
pneumonia due to bacterial colonization and aspirations
in the stomach [11]. Therefore, the aim of this study is to
evaluate whether the long-term (≥4 weeks) use of PPIs has
an effect on the mortality and morbidity of patients who
are hospitalized for COVID-19.
2. Materials and methods
In this multicentric retrospective study, 382 adult patients
(≥18 years of age) with confirmed COVID-19 who were
hospitalized for treatment were enrolled. This study was
approved by the Local Ethics Committee of Lokman
Hekim University, Ankara, Turkey.
Diagnosis of COVID-19 was confirmed using
nasopharyngeal swab real-time reverse transcriptase PCR
according to the WHO guidelines1. Patients were treated
in line with the recommendations of the Turkish Health
Ministry COVID-19 adult patient treatment guidelines2.
Demographic features, complete medical history, and the
laboratory findings of the study participants at admission
were obtained from the medical records. Patients under
any other type of antisecretory medication (H2 receptor
antagonists) were not included in the study. Patients
with missing data (n = 21), patients with any known
malignancies (n = 5), patients under immunosuppressive
therapy (n = 4), and patients under 18 years of age (n = 2)
were also excluded from the study. In total, 411 patients
were evaluated for the study, 29 of whom were excluded
according to the exclusion criteria, ultimately leading to
the inclusion of 382 patients.
Some data in the literature have supported the notion
that using PPIs increases the risk of pneumonia during the

first month of therapy. Therefore, we determined the cutoff
for the use of PPIs as 4 weeks [12]. Patients were divided
into two groups according to the periods during which
they used PPIs: the first group included those who were
not on PPI treatment, and the second group included those
who have used PPIs for more than 4 weeks. Patients taking
any type of PPIs from time to time were not included in
the study.
Age, sex, the presence of comorbid diseases,
medications used, duration of drug use, smoking habits,
treatments received after the diagnosis of the disease,
whether these patients were admitted to the intensive
care unit or not, and whether they were intubated were
recorded with their outcomes. Those whose treatment or
hospitalization periods were still ongoing during the data
collection were not included in the study.
2.1. Statistical analysis
All statistical analyses were performed using IBM
SPSS Statistics v. 22.0 (IBM Corp., Armonk, NY, USA).
Independent student’s t-test and one-way analysis of
variance (ANOVA) were used for continuous variables,
and the results are presented as the mean ± standard
deviation. The chi-square test was used for categorical
variables in independent groups, and the results
are presented as numbers and percentages. Normal
distribution for continuous variables was evaluated with
the Kolmogorov–Smirnov test. The Mann–Whitney U
test was used to perform a comparative analysis between
the two independent groups. Cox regression analysis was
used to evaluate the risk factors related to intubation and
mortality. A p-value of 0.05 was regarded as statistically
significant.
3. Results
A total of 382 patients were included in this study and
divided into two groups according to their PPI usage
history over the last 6 months: 291 patients reported that
they did not use any type of PPI over the last 6 months,
and 91 patients reported using PPIs for more than 4 weeks
(lansoprazole, n = 12; esomeprazole, n = 10; pantoprazole,
n = 58; and rabeprazole, n = 11).
Table 1 summarizes the demographic characteristics
of the study participants as well as their patterns of use
of PPIs. Those who reported using PPIs for more than 4
weeks were found to be significantly older (p = 0.001).
Regarding the presence of comorbid chronic diseases (e.g.,
hypertension, diabetes, asthma, or chronic obstructive
pulmonary disease), hypertension, and diabetes were
found to be significantly more common in the PPI-using
group (Table 1). No significant difference was found

Organization WH. Assessment tool for laboratories implementing COVID-19 virus testing: interim guidance . Website. https://apps.who.int/iris/
handle/10665/331714 [acessed on ].
1

Bakanligi TCS. COVID-19 (SARS-CoV-2 ENFEKSİYONU) ERİŞKİN HASTA TEDAVİSİ. Website https://covid19.saglik.gov.tr/TR-66926/eriskinhasta-tedavisi.html [acessed on ].
2
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Table 1. Demographic characteristics according to PPI therapy.
PPI Therapy
Parameters

No current PPI use (G1)
n=291

>4 weeks PPI use (G2)
n=91

p

Age, years
Median (IQR)

49 (32-66)

70 (59-77)

<0.001*

Sex, n (%)
Female

111 (38.1)

32 (35.2)

Male

180 (61.9)

59 (64.8)

Current smoking status, n (%)
No

219 (75.3)

50 (54.9)

Yes

72 (24.7)

41 (45.1)

Comorbidities, n (%)
No

160 (55)

12 (13.2)

Yes

131 (45)

79 (86.8)

Hypertension, n (%)
No

187 (67.8)

36 (39.6)

Yes

89 (32.2)

55 (60.4)

ACE inh or ARB Therapy, n (%)
No

211 (78.7)

45 (50.6)

Yes

57 (21.3)

44 (49.4)

Diabetes mellitus, n (%)
No

226 (82.8)

64 (71.9)

Yes

47 (17.2)

25 (28.1)

Antidiabetic Therapy, n (%)
No

238 (88.1)

64 (72.7)

Yes

32 (11.9)

24 (27.3)

Place of treatment, n (%)
Pandemic service

245 (84.2)

54 (59.3)

Intensive care unit

46 (15.8)

37 (40.7)

Intubation, n (%)
No (IQR)

254 (87.3)

52 (57.1)

Yes
Exitus, n (%)
No

37 (12.7)

39 (42.9)

254 (87.3)

57 (62.6)

Yes

37 (12.7)

34 (37.4)

0.6**

<0.001**

<0.001**

<0.001**

<0.001**

0.026**

0.001**

<0.001**

<0.001**
<0.001**

Duration of stay in hospital, day
0.298*
Median (IQR)
14 (8-14)
13 (7-18)
Duration of stay in ICU, day
0.259*
Median (IQR)
8 (4-13)
8 (5-20)
*Mann–Whitney U test; **Chi-Square test; PPI: proton pump inhibitor; ACE inh: angiotensin converting enzyme
inhibitor; ARB: angiotensin receptor blocker; ICU: intensive care unit.

between groups regarding the distribution of medications
used for the treatment of COVID-19 (p > 0.05).
Table 2 summarizes the results of the Cox regression
analysis for intubation and mortality. According to the

Cox regression analysis, current smoking, the use of
an angiotensin converting enzyme (ACE) inhibitor or
angiotensin receptor blocker (ARB), and PPI therapy for
more than 4 weeks were found to be independent risk

1677

1678
Table 2. The evaluation of risk factors related to intubation and mortality with regression analyses (n = 382).
Risk factors related to intubation

Risk factors related to mortality
Multivariate LR model

Univariate COX regression
(CR) analysis

Multivariate CR model

Crude OR (95%CI)

P

Adjusted OR (95% CI) P

Crude HR (95% CI)

P

Adjusted HR (95% CI)

P

Sex
(ref: male)

1.114 (0.665–1.865)

0.682

3.022 (1.183–7.719)

0.021

1.418 (0.882–2.281)

0.150

1.533 (0.802)

0.196

Age

1.056 (1.039–1.074)

<0.001

1.039 (1.014–1.065)

0.002

1.043 (1.028–1.059)

<0.001

1.047 (1.026–1.068)

<0.001

Current smoking*
(ref: no)

4.723 (2.784–8.011)

<0.001

9.364 (3.769–23.267)

<0.001

2.011 (1.231–3.284)

0.005

2.590 (1.334–5.025)

0.005

Hypertension
(ref: no)

6.633 (3.681–11.953)

<0.001

0.497 (0.156–1.584)

0.237

3.187 (1.859–5.464)

<0.001

0.937 (0.400–2.192)

0.880

Diabetes mellitus
(ref: no)

2.696 (1.492–4.873)

0.001

0.785 (0.351–1.756)

0.556

2.107 (1.250–3.551)

0.005

1.271 (0.719–2.246)

0.409

ACE inh or ARB use
(ref: no use)

8.992 (4.963–16.293)

<0.001

5.363 (1.870–15.382)

0.002

2.566 (1.529–4.305)

<0.001

0.937 (0.433–2.028)

0.870

PPI therapy, ≥4 weeks PPI use
(ref: no use)

5.149 (3.001–8.833)

<0.001

4.532 (2.233–9.200)

<0.001

1.944 (1.188–3.182)

0.008

1.83 (1.065–2.419)

0.031

PPI: proton pump inhibitor; ACE inh: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; OR: odds ratio; HR: hazard ratio; CI: confidence interval.
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factors for intubation. In addition, older age (HR: 1.047,
95% CI: 1.026–1.068), current smoking (HR: 2.590,
95% CI: 1.334–5.025), and PPI therapy for more than 4
weeks (HR: 1.83, 95% CI: 1.06–2.41) were found to be
independent risk factors for mortality.
4. Discussion
The results obtained in this study show that using PPIs for
more than 4 weeks is an independent risk factor for both
intubation and mortality. For patients with COVID-19,
which is currently affecting millions of people worldwide
and is causing high rates of mortality, it is critical to
determine the risk factors that may lead to intubation
requirement and mortality.
In general, PPIs are one of the most frequently
prescribed drugs worldwide. Long-term PPI use has been
related to some adverse events associated with vitamin
absorption and alterations in intestinal microbiota [13].
These effects are associated with hypochlorhydria, which
disturbs the body’s defenses against ingested viruses and
bacteria [14].
Data regarding the effects of long-term PPI use on
the outcomes of patients diagnosed with COVID-19 have
rapidly increased. For example, recently, Almanaro et al.
found a dose–response relationship between COVID-19
positivity and PPI use, and they found that patients who
take PPIs twice a day are at an increased risk for testing
positive for COVID-19 on PCR [15]. In general, the
normal pH level is 3 or less in a healthy stomach. While
this acidic environment impairs the infectivity of SARSCoV-1, the virus responsible for severe acute respiratory
syndrome, the higher pH resulting from the use of PPIs
does not inactivate the virus [16].
SARS-CoV-2 can enter the body via the gastrointestinal
(GI) system through the angiotensin-converting enzyme
2 receptor, which is widely expressed in the GI system
[17,18]. This helps the virus spread easily outside the GI
system and cause inflammation in other systems [19]. The
gut microbiota plays an essential role in the regulation
of metabolic, defensive, and immunological processes in
the human body. Any change in the microbial balance,
namely, dysbiosis, can directly affect the immunological
response [20–22]. PPIs cause hypoacidity, which results
in negative effects on the stomach functions and defense
mechanisms of the body, leading to decreased gastric
mucus viscosity, delayed gastric emptying, and increased
bacterial translocation and bacterial load [23]. Impairment
of neutrophil functions induced by PPI use can impair
the body’s ability to recover from an infection and may
contribute to harmful outcomes for an infection [24]. In
this respect, our results reporting the negative effects of
PPI use for more than 4 weeks on intubation requirement
and mortality rates of patients with COVID-19 may

be associated with the altered immunity and intestinal
microbiota of the patients using PPIs.
Several recently published studies have shown that
using PPIs is associated with poor outcomes for patients
with COVID-19. In a national cohort study by Lee et al., the
authors found that using PPIs is associated with mortality
(adjusted OR: 1.79, 95% CI: 1.3–3.1) and poor clinical
outcomes. However, since these data have been taken from
electronic health records, they may not match the actual
usage data [25]. In another study, Ramachandran et al.
showed that, in 295 patients hospitalized for COVID-19,
prehospitalization PPI exposure is an independent risk
factor for mortality (OR: 2.33, 95% CI: 1.18–4.59) [26].
It has also been shown that H2 receptor blockers do
not increase but rather decrease the risk of mortality
for patients with COVID-19 [15,27]. In a pooled metaanalysis, Hariyanto et al. [28] also showed that using
PPIs is associated with a significant increase in the risk of
severe COVID-19. However, in all of these reports, data
on the duration or type of PPIs used were not available or
standardized. In contrast to these findings, in an opinion
paper evaluating the data of many studies, the potential
benefits of using PPIs in the treatment of COVID-19 were
evaluated, and it was stated that PPIs may be effective in
the treatment of COVID-19 [29].
This study has several limitations, the most important
of which are the small number of patients included and
its retrospective design. All the data were obtained
from hospital records and patient databases. We did not
evaluate the presence of pneumonia in our patients, which
is considered another limitation of this study. Therefore,
we were unable to suggest a direct association between PPI
use and pneumonia. Although our two groups were not
balanced in terms of age, smoking habits, and the presence
of comorbidities, this did not affect the results thanks to
the significant findings obtained in the regression analysis.
Because of the highly common use of these medications,
larger prospective, randomized, controlled studies are
warranted to determine the direct effects of long-term PPI
use on the outcomes of patients with COVID-19.
In conclusion, we found that using PPIs for more than
4 weeks is associated with negative outcomes for patients
with COVID-19. Therefore, patients under PPI therapy
should be evaluated more carefully if they are hospitalized
for COVID-19.
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